Millennium chief scientist takes offbeat approach

The Scientist profiles Millennium Pharmaceuticals CSO Joe Bolen, whose team has been advancing a new therapy that targets molecules "upstream" from Velcade. The data will be released at the American Association of Cancer Research meeting. "We'll be the belles of the ball at AACR with this one," says Bolen, whose scientific journey started at the University of Nebraska and wound through 10 years of work at the NIH, where he won the institute's Meritorious Research for his work on protein tyrosine kinase oncogenes.

- read the profile in The Scientist

Related Articles:
Millennium spent $1.3M on lobbying. Report
Positive Velcade data fuels stock rise. Report
Millennium to buy AnorMed for $515M. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.